Different expression of miR-29b and VEGFA in glioma

Artif Cells Nanomed Biotechnol. 2016 Dec;44(8):1927-1932. doi: 10.3109/21691401.2015.1111237. Epub 2015 Nov 30.

Abstract

Glioma is one of the most common carcinomas in terms of both incidence and mortality worldwide. This is a case-control study with 240 cases and age- and gender-matched controls in the rate of 1:1. The results of this present word indicated that the expressions of both miR-29b and VEGFA in blood were significantly different compared with the control group, and thus may help to differentiate glioma cases from the controls. In addition, the diagnostic role of miR-29b and VEGFA was important for the clinical application. In conclusion, circulating miR-29b and VEGFA could be used as diagnosis biomarkers.

Keywords: case–control; diagnosis; glioma; microRNA.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / biosynthesis*
  • Brain Neoplasms / metabolism*
  • Brain Neoplasms / mortality
  • Case-Control Studies
  • Disease-Free Survival
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Glioma / metabolism*
  • Glioma / mortality
  • Humans
  • Male
  • MicroRNAs / biosynthesis*
  • Middle Aged
  • Neoplasm Proteins / biosynthesis*
  • RNA, Neoplasm / biosynthesis*
  • Survival Rate
  • Vascular Endothelial Growth Factor A / biosynthesis*

Substances

  • Biomarkers, Tumor
  • MIRN29a microRNA, human
  • MicroRNAs
  • Neoplasm Proteins
  • RNA, Neoplasm
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A